Back

Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Oral anticoagulant therapy for atrial fibrillation in clinical practice Oral Anticoagulation ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Hideki Kitahara

Chiba University Graduate School of Medicine, Chiba (Japan)

7 More presentations in this session

Presentation thumbnail
Temporal trends of prescription rates, dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in patients with atrial fibrillation
Doctor T. Chao (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Persistence and predictors for non-persistence to edoxaban therapy in patients with atrial fibrillation: 4-year follow-up data from the ETNA-AF-Europe study
Associate Professor I. Diemberger (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Impact of resumption of Oral AntiCoagulation therapy (OAC) after GastroIntestinal Bleeding (GIB) on clinical outcomes in patients with Non-Valvular Atrial Fibrillation (NVAF)
Doctor W. Sun (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
The efficacy and safety of NOAC in very elderly atrial fibrillation patients; data from the Korean national health insurance cohort registry
Doctor S. Choi (Incheon, KR)
Abstract Slides Video
Presentation thumbnail
Impact of body weight and body mass index on clinical outcomes of edoxaban therapy in atrial fibrillation patients included in the ETNA-AF-Global registry
Professor G. Boriani (Modena, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Oral anticoagulant therapy for atrial fibrillation in clinical practice

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of under-dose non-vitamin K antagonist oral anticoagulant with atrial fibrillation undergoing PCI: Insights from a nationwide population-based cohort study
thumbnail
Congress Presentation
Impact of different dose reduction criteria on dose assignment of current DOACs and related outcomes: an analysis from 4-year data of the ETNA-AF Europe programme
thumbnail
Congress Presentation
Temporal trends of prescription rates, dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in patients with atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources